Nicergoline reverts haloperidol-induced loss of detoxifying-enzyme activity

Eur J Pharmacol. 2004 Nov 28;505(1-3):121-5. doi: 10.1016/j.ejphar.2004.10.016.

Abstract

We evaluated the effects of nicergoline on antioxidant defense enzymes (detoxifying enzymes), during chronic treatment with haloperidol in rats. Chronic use of haloperidol (10 weeks, 1.5 mg/kg/day) induces a significant decrease in glutathione reductase, glutathione peroxidase and superoxide dismutase activity, in selected areas of the brain. Co-administration of nicergoline (20 days, 10 mg/kg/day) significantly restored the activity of these enzymes to levels comparable to those observed in control rats. These observations suggest beneficial effects of nicergoline in the prevention and in the treatment of haloperidol-induced side effects.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Brain / drug effects*
  • Brain / enzymology
  • Cerebellum / drug effects
  • Cerebellum / enzymology
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / enzymology
  • Corpus Striatum / drug effects
  • Corpus Striatum / enzymology
  • Glutathione Peroxidase / metabolism
  • Glutathione Reductase / metabolism
  • Haloperidol / pharmacology*
  • Male
  • Nicergoline / pharmacology*
  • Oxidoreductases / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / metabolism

Substances

  • Oxidoreductases
  • Glutathione Peroxidase
  • Superoxide Dismutase
  • Glutathione Reductase
  • Haloperidol
  • Nicergoline